PE20020833A1 - CHEMOTHERAPIC COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIOAVAILABILITY - Google Patents
CHEMOTHERAPIC COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIOAVAILABILITYInfo
- Publication number
- PE20020833A1 PE20020833A1 PE2002000030A PE2002000030A PE20020833A1 PE 20020833 A1 PE20020833 A1 PE 20020833A1 PE 2002000030 A PE2002000030 A PE 2002000030A PE 2002000030 A PE2002000030 A PE 2002000030A PE 20020833 A1 PE20020833 A1 PE 20020833A1
- Authority
- PE
- Peru
- Prior art keywords
- paclitaxel
- composition
- microemulsion
- polyoxyl
- diglyceride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229930012538 Paclitaxel Natural products 0.000 title abstract 4
- 229960001592 paclitaxel Drugs 0.000 title abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 4
- 239000004530 micro-emulsion Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 229920002675 Polyoxyl Polymers 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- -1 FATTY ACID ESTERS Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) PACLITAXEL; b) UN SURFACTANTE SELECCIONADO DE ACEITE DE RICINO HIDROGENADO POLIOXIL 40, ACEITE DE RICINO HIDROGENADO POLIOXIL 35, ESTERES DE ACIDOS GRASOS POLIOXIETILENADOS SEL SORBITAN, ENTRE OTROS ; c) UN SOLVENTE SELECCIONADO DE POLIETILENGLICOL, PROPILENGLICOL, ETANOL, GLICEROL, ENTRE OTROS Y d) UN POLIMERO CELULOSICO SUSTITUIDO. LA PROPORCION EN PESO DE PACLITAXEL AL SURFACTANTE OSCILA ENTRE 1:5 Y 1:10. LA COMPOSICION CONTIENE ADEMAS UN INHIBIDOR DE LA GLICOPROTEINA P COMO ALGINATO, XANTANO, VERAPAMILO, CICLOSPORINA A Y ADICIONALMENTE UN DIGLICERIDO O UNA MEZCLA DE DIGLICERIDO Y MONOGLICERIDO. LA COMPOSICION GENERA UNA MICROEMULSION SOBRESATURADA DE PACLITAXEL AL ENTRAR EN CONTACTO CON AGUA AUMENTANDO DE ESTA FORMA LA BIODISPONIBILIDAD ORAL DEL FARMACO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DEL CANCERIT REFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING: a) PACLITAXEL; b) A SURFACTANT SELECTED FROM POLYOXYL 40 HYDROGENATED RICHINO OIL, POLYOXYL 35 HYDROGENATED RICHINE OIL, SORBITAN SEL-SORBITAN POLYOXYETHYLENED FATTY ACID ESTERS, AMONG OTHERS; c) A SOLVENT SELECTED FROM POLYETHYLENE GLYCOL, PROPYLENE GLYCOL, ETHANOL, GLYCEROL, AMONG OTHERS AND d) A SUBSTITUTE CELLULOSIC POLYMER. THE RATIO BY WEIGHT OF PACLITAXEL TO THE SURFACTANT RANGES BETWEEN 1: 5 AND 1:10. THE COMPOSITION ALSO CONTAINS A GLYCOPROTEIN P INHIBITOR SUCH AS ALGINATE, XANTHANE, VERAPAMYL, CYCLOSPORIN A AND ADDITIONALLY A DIGLYCERIDE OR A MIXTURE OF DIGLYCERIDE AND MONOGLYCERIDE. THE COMPOSITION GENERATES AN OVERRESATURATED MICROEMULSION OF PACLITAXEL WHEN IT COMES IN CONTACT WITH WATER, IN THIS WAY INCREASING THE ORAL BIODAVAILABILITY OF THE DRUG. THE COMPOSITION IS USEFUL FOR THE TREATMENT OF CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26255501P | 2001-01-18 | 2001-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020833A1 true PE20020833A1 (en) | 2002-09-19 |
Family
ID=22998000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000030A PE20020833A1 (en) | 2001-01-18 | 2002-01-17 | CHEMOTHERAPIC COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIOAVAILABILITY |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1365759A2 (en) |
| JP (1) | JP2004520398A (en) |
| AR (1) | AR032642A1 (en) |
| CA (1) | CA2434641A1 (en) |
| MX (1) | MXPA03006404A (en) |
| NZ (1) | NZ539046A (en) |
| PE (1) | PE20020833A1 (en) |
| WO (1) | WO2002064132A2 (en) |
| ZA (1) | ZA200305086B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| KR100533458B1 (en) | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | Composition for solubilization of paclitaxel and preparation method thereof |
| EP1498143A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| EP1498120A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
| US20050123602A1 (en) * | 2003-09-25 | 2005-06-09 | Michaelis Arthur F. | Rifalazil formulations |
| KR20080030024A (en) * | 2005-06-17 | 2008-04-03 | 호스피라 오스트레일리아 피티와이 리미티드 | Pharmaceutical Liquid Formulations of Docetaxel |
| ES2744816T3 (en) * | 2006-10-27 | 2020-02-26 | Capsugel Belgium Nv | Hydroxypropyl methyl cellulose hard capsules and manufacturing process |
| US20090088393A1 (en) * | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| KR101053780B1 (en) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | Single liquid stable pharmaceutical composition containing docetaxel |
| RU2603833C2 (en) * | 2010-11-08 | 2016-11-27 | Кадила Фармасьютикалз Лимитед | Pharmaceutical composition of taxoids |
| CN103110581B (en) * | 2013-02-26 | 2015-07-22 | 西南大学 | Taxol microemulsion drug composition and preparation method thereof |
| KR101542364B1 (en) * | 2014-10-31 | 2015-08-07 | 대화제약 주식회사 | Pharmaceutical composition for oral administration comprising taxanes |
| ES2895948T3 (en) | 2015-07-30 | 2022-02-23 | Dae Hwa Pharma Co Ltd | Pharmaceutical composition for oral administration comprising taxane at high concentration |
| CN107028931A (en) * | 2016-02-04 | 2017-08-11 | 上海宣泰医药科技有限公司 | A kind of taxol drug composition and its pharmaceutical preparation, preparation method and purposes |
| EP3701943A1 (en) * | 2019-02-26 | 2020-09-02 | CAPNOMED GmbH | Delayed delivery of anticancer drugs |
| IL316629A (en) * | 2022-05-11 | 2024-12-01 | Lilly Co Eli | Glp1 pharmaceutical compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| EP0868422A1 (en) * | 1996-09-24 | 1998-10-07 | Marigen S.A. | Ultramicroemulsion of spontaneously dispersible concentrates of esters of baccatin-iii compounds with antitumor and antiviral effect |
| CH688504A5 (en) * | 1997-03-26 | 1997-10-31 | Marigen Sa | Spontaneously dispersible concentrate containing a taxol analogue |
| ATE308365T1 (en) * | 1997-05-27 | 2005-11-15 | Ivax Research Inc | COMPOSITIONS FOR ORAL ADMINISTRATION OF TAXANS AND THEIR USE |
| AU3574097A (en) * | 1997-06-20 | 1999-01-04 | Baker Norton Pharmaceuticals, Inc. | Soluble prodrugs of paclitaxel |
| IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
| US6638522B1 (en) * | 1998-12-11 | 2003-10-28 | Pharmasolutions, Inc. | Microemulsion concentrate composition of cyclosporin |
| ATE312601T1 (en) * | 1999-05-27 | 2005-12-15 | Acusphere Inc | POROUS MEDICINAL MATRICES AND THEIR PRODUCTION PROCESS |
| US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| US6919370B2 (en) * | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
-
2002
- 2002-01-14 WO PCT/US2002/000497 patent/WO2002064132A2/en not_active Ceased
- 2002-01-14 EP EP02718808A patent/EP1365759A2/en not_active Withdrawn
- 2002-01-14 CA CA002434641A patent/CA2434641A1/en not_active Abandoned
- 2002-01-14 JP JP2002563926A patent/JP2004520398A/en active Pending
- 2002-01-14 MX MXPA03006404A patent/MXPA03006404A/en unknown
- 2002-01-14 NZ NZ539046A patent/NZ539046A/en unknown
- 2002-01-17 AR ARP020100158A patent/AR032642A1/en unknown
- 2002-01-17 PE PE2002000030A patent/PE20020833A1/en not_active Application Discontinuation
-
2003
- 2003-06-30 ZA ZA200305086A patent/ZA200305086B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR032642A1 (en) | 2003-11-19 |
| CA2434641A1 (en) | 2002-08-22 |
| WO2002064132A2 (en) | 2002-08-22 |
| ZA200305086B (en) | 2004-06-30 |
| NZ539046A (en) | 2006-11-30 |
| JP2004520398A (en) | 2004-07-08 |
| WO2002064132A3 (en) | 2003-05-30 |
| MXPA03006404A (en) | 2004-12-02 |
| EP1365759A2 (en) | 2003-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020833A1 (en) | CHEMOTHERAPIC COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIOAVAILABILITY | |
| BRPI0511966A (en) | pharmaceutical compositions containing polyethylene glycol having a molecular weight less than 600 daltons | |
| RU2014102013A (en) | DEVICE FOR LOCAL AND / OR REGIONAL DELIVERY USING LIQUID COMPOSITIONS OF THERAPEUTICALLY ACTIVE SUBSTANCES | |
| BRPI0409185A (en) | topical anthelmintic veterinary formulations | |
| MX373796B (en) | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same | |
| CR20110131A (en) | PROSTAGLANDINAS DERIVATIVES | |
| AR037490A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES | |
| CO5570649A2 (en) | ANTITRANSPIRANT PRODUCT IN HIGH EFFICIENCY LIQUID GEL | |
| ECSP088239A (en) | COMPOSITION OF SUSTAINED DRUG RELEASE | |
| AR070033A1 (en) | INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USES | |
| AR090603A2 (en) | PARENTERAL COMPOSITION AND PROCEDURE FOR PREPARATION | |
| ES2530390T3 (en) | Foaming vehicle of carboxylic acid and pharmaceutical compositions thereof | |
| MA30765B1 (en) | INNOVATIVE DERIVATIVES OF THIOPHENE | |
| MA31953B1 (en) | New derivatives of thiophene. | |
| BRPI0511036A (en) | 17-aag pharmaceutical solution formulations | |
| MA34296B1 (en) | INJECTABLE RETARDANT ANTIPSYCHOTIC COMPOSITION | |
| EA200301019A1 (en) | ORGANIZED PHARMACEUTICAL COMPOSITION, INCLUDING A DRUG WITH LOW SOLUBILITY IN WATER (COX-2 INHIBITOR), SOLVENT, FATTY ACID, AND ORGANIC AMINE | |
| ES2192234T3 (en) | PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF 2-ARILPROPIONIC ACIDS. | |
| AR046878A1 (en) | ENDOPARASITICIDE AGENT FOR TOPICAL ADMINISTRATION | |
| AR039190A1 (en) | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT UNDERSTANDING THE COMPOUND | |
| PE20061327A1 (en) | COMBINATIONS OF BENZOFURAN DERIVATIVES AND AN ANTIDEPRESSANT FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
| PE20001110A1 (en) | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION, AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT | |
| TR200401436T4 (en) | Pharmaceutical composition containing pemetrexed with monothioglycerol, L-system or thioglycolic acid | |
| CY1105318T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPICAL ADMINISTRATION | |
| BR0111678A (en) | Medicinal compositions containing propenone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |